Detection of precancer cervical lesions with methylation markers in urine

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON23501

Enrollment

100

Registered

2017-06-02

Start date

2017-06-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methylation markers, cervix carcinoma, CIN2, CIN3, CIN, urine analysis

Interventions

No interventions. Only collection of 90 cc urine and a cervicovaginal self sample before treatment

Eligibility

Inclusion criteria

Inclusion criteria: - >18 years old - eligible for LLETZ

Exclusion criteria

Exclusion criteria: - other cancer elsewhere

Design outcomes

Primary

Measure	Time frame
Concordance between HPV DNA detection and DNA methylation analysis in urine and a cervicovaginal self sample	—

Secondary

Measure	Time frame
Performance of biomarkers in urine for detection of CIN2+ or CIN3+, and compared with the performance of this test in cervicovaginal self samples	—

Contacts

Public ContactM.C. van Ruiten

m.vanruiten@vumc.nl020-4440909

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)